Novartis’s Early HTA Engagement Pays Off With Luxturna
NICE’s rapid decision to recommend funding in England and Wales for Novartis’s gene therapy Luxturna is a result of what the company calls its "collaborative and transparent" approach to negotiations over the health technology assessment of innovative new therapies. Novartis explains why this appraisal process was completed so quickly.
You may also be interested in...
New models of paying for gene therapies will emerge as more of these innovative treatments, particularly outside the rare disease and oncology spaces, hit the market.
Novartis/Spark’s Luxturna has been authorized by NICE for use in England after the company agreed a discount on the list price that made the gene therapy cost effective for the national health service. The recommendation was made in record time thanks to good collaboration between the two parties.
Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.